Plain-English translation of NCT06350994 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is studying whether CAR-T cell therapy — a powerful immunotherapy that uses your own immune cells to fight blood cancers — can affect your heart. Researchers want to check your heart health carefully in the days right after you receive this treatment, using ultrasound and blood tests, to understand whether and how often heart problems occur and what causes them.
While this treatment has helped many patients with hard-to-treat blood cancers, it can trigger a strong inflammatory response in the body that sometimes affects the heart. Doctors want to catch any heart changes early, even ones without obvious symptoms, so they can better understand and prevent these complications in future patients.
You likely qualify if…
You likely don't qualify if…
You will receive a heart ultrasound (echocardiography) done at your bedside between days 3 and 5 after your CAR-T cell infusion. This will be combined with routine heart monitoring tests including an electrocardiogram, blood tests to check for heart damage markers, and blood work to measure inflammatory markers. The entire process is non-invasive and designed to be done while you are already in the hospital receiving your cancer treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
France
Enrollment target
~60 participants
Started
November 2024
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jérémie JOFFRE, MD, PhD
Assistance Publique - Hôpitaux de Paris
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.